Board of Directors of the Company at their meeting held on Tuesday, August 12, 2025 , have discussed the following matters: 1. Approved the Un-Audited Financial Results of the Company ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved the unaudited Q1 FY26 results (quarter ended June 30, 2025) showing zero revenue from operations and a sharp surge in administrative expenses to about Rs. 1.18 crore, dragging the company to a loss of Rs. 1.18 crore versus a profit of Rs. 24.66 lakh in the year-ago quarter. EPS turned deeply negative at Rs. -78.70. The board also approved the 83rd AGM notice for September 24, 2025 with book closure from September 17-24. Notably, the company plans to change its name, amend its main objects to venture into wholesale and commodity trading, and shift its registered office from Maharashtra (Kalyan) to Gujarat (Ahmedabad), signalling a full pivot away from its current pharma operations.
Shareholders should note that core pharma revenue is effectively zero and the quarterly loss is unusually large, suggesting the pivot to commodity trading is a make-or-break move. The name change, registered office shift, and entry into a completely different business make this a high-risk transition for retail investors, with stock price likely to react to the weak Q1 numbers and uncertainty around the new direction.